Diabetes
Refine Search
Pharmaceutical
CeQur on Tuesday said it has set up a unit in Wales following another round of $100 million investment from Arthurian Life Sciences and that it plans to launch its new insulin infusion device in Europe and the USA in 2016. 1 September 2015
Pharmaceutical
The US Food and Drug Administration is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin and alogliptin may cause joint pain that can be severe and disabling. 30 August 2015
Pharmaceutical
Developed by Danish diabetes care giant Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes, notes a new report from Research and Markets. 30 August 2015
Pharmaceutical
The US Food and Drug Administration has approved Synjardy (empagliflozin and metformin hydrochloride) tablets, from German family-owned pharma major Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. 28 August 2015
Pharmaceutical
In what has been a busy news week for Novo Nordisk, the Danish diabetes care giant said today that it has entered into a definitive agreement to acquire Calibrium and MB2, two privately-held biopharmaceutical research companies based in Indiana, USA. 27 August 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk plans to invest an estimated $2 billion over the next five years in new production facilities in Clayton, North Carolina, USA, and in Mlv, Denmark. 26 August 2015
Pharmaceutical
German family-owned Boehringer Ingelheim and US pharma major Eli Lilly yesterday announced positive top-line results from EMPA-REG OUTCOME with their jointly developed diabetes drug Jardiance (empagliflozin). 21 August 2015
Biotechnology
Biopharmaceutical company, Intarcia Therapeutics reported positive results from Phase III clinical trials for its drug candidate to treat type 2 diabetes. 19 August 2015
Biotechnology
Boehringer Ingelheim and USA-based biotech firm Circuit Therapeutics have entered into a second collaboration using Circuit’s proprietary optogenetics technology platform. 14 August 2015
Pharmaceutical
Australia’s regulator the Therapeutic Goods Administration (TGA) is advising consumers and health professionals that serious cases of diabetic ketoacidosis (DKA) have been reported in patients taking prescription medicines that are inhibitors of sodium glucose co-transporter 2 (SGLT2). 14 August 2015
Biotechnology
In a second deal between the companies this year, German biotech firm Evotec has entered into a strategic collaboration with French pharma major Sanofi in the field of diabetes. 10 August 2015
Pharmaceutical
Novo Nordisk this morning posted first-half 2015 results, saying that sales increased 25% in Danish kroner and 9% in local currencies to 52.3 billion kroner ($7.75 billion). 6 August 2015
Pharmaceutical
Boehringer Ingelheim this morning posted first-half 2015 results, showing that group sales rose a modest 2% to around 7.4 billion euros ($8.18 billion) compared with the same period in the previous year. 4 August 2015
Pharmaceutical
In a US federal court victory for Indian drugmaker Ranbaxy, in a suit that was the first test of what antitrust limits may be placed on reverse payment deals among drugmakers. 2 August 2015
Pharmaceutical
Co-administration of the oral antidiabetic agent repaglinide and oral antiplatelet drug clopidogrel (a known CYP2C8 inhibitor), may lead to a significant decrease in blood glucose levels due to a drug-drug interaction, according to a recent recall and alerts posting on pharma regulator Health Canada’s web site. 1 August 2015
Pharmaceutical
Takeda Pharmaceutical says it has completed the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study for pioglitazone containing medicines. 31 July 2015
Biosimilars
Pharma giant Merck & Co on Tuesday raised its outlook for full-year profit while posting a second-quarter earnings ahead of estimates despite a drop in sales. 29 July 2015
Pharmaceutical
French drug major Sanofi on Wednesday said the LixiLan-O phase III trial for its drug candidate to treat type 2 diabetes has met its primary endpoint. 29 July 2015
Biotechnology
Hong Kong-listed biotech firm 3SBio has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical. 24 July 2015
Pharmaceutical
New research indicates that the global market for type 2 diabetes mellitus (T2DM) therapeutics will rise in value from $23.5 billion in 2014 to an estimated $39 billion by 2021. 24 July 2015
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze